Evidence map›Paper›PMID 34302897›Full record

ReviewAdvanced drug delivery reviews2021

Drug delivery carriers with therapeutic functions.

Shuting S Cai, Tianyu Li, Tolulope Akinade, Yuefei Zhu, Kam W Leong

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Advanced drug delivery reviews, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Food science & nutrition · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shuting S CaiDepartment of Biomedical Engineering, Columbia University, New York 10027, New York, United States.
Tianyu LiDepartment of Biomedical Engineering, Columbia University, New York 10027, New York, United States.
Tolulope AkinadeGraduate Program in Cellular, Molecular and Biomedical Studies, Vagelos College of Physicians and Surgeons, Columbia University, New York 10027, New York, United States.
Yuefei ZhuDepartment of Biomedical Engineering, Columbia University, New York 10027, New York, United States.
Kam W LeongDepartment of Biomedical Engineering, Columbia University, New York 10027, New York, United States; Department of Systems Biology, Columbia University, New York 10027, New York, United States. Electronic address: kwl2121@columbia.edu.

Funding

Targeting Endosomal Receptors for Treatment of Chronic PainR01DE029951 · NIDCR · NEW YORK UNIVERSITY · PI BUNNETT, NIGEL W, SCHMIDT, BRIAN L · 2020 to 2024
$4.7M
Engineering Polymers to Scavenge DAMPs in Arthritis and LupusR01AR073935 · NIAMS · DUKE UNIVERSITY · PI LEONG, KAM W, SULLENGER, BRUCE ALAN · 2018 to 2022
$3.3M
Design and Application of Cationic Nanocarriers to Inhibit Breast Cancer Progression in Primary and Metastatic SitesF31CA257399 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI AKINADE, TOLULOPE OLATOKUNBO · 2021 to 2023
$118k
NCI NIH HHS F31 CA257399NIAMS NIH HHS R01 AR073935NIDCR NIH HHS R01 DE029951
6 · The paper itself

Abstract

Design of micro- or nanocarriers for drug delivery has primarily been focused on properties such as hydrophobicity, biodegradability, size, shape, surface charge, and toxicity, so that they can achieve optimal delivery with respect to drug loading, release kinetics, biodistribution, cellular uptake, and biocompatibility. Incorporation of stimulus-sensitive moieties into the carriers would lead to "smart" delivery systems. A further evolution would be to endow the carrier with a therapeutic function such that it no longer serves as a mere passive entity to release the drug at the target tissue but can be viewed as a therapeutic agent in itself. In this review, we will discuss recent and ongoing efforts over the past decade to design therapeutic drug carriers that confer a biological benefit, including ROS scavenging or generating, pro- or anti-inflammatory, and immuno-evasive properties, to enhance the overall therapeutic efficacy of the delivery systems.

Indexed as

Drug Delivery SystemsAnimalsHumansReactive Oxygen SpeciesReactive Oxygen SpeciesAnti-bacterialAnti-fibroticAnti-inflammatoryAnti-microbialDrug deliveryImmunoadjuvantROS generationROS scavengingTherapeutic carriers

Identifiers

PMID34302897
PMCPMC8440421

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.